Potential blood biomarker for disease severity in the taiwanese population with Alzheimer's disease

American Journal of Alzheimer's Disease and other Dementias

Volumn 28, Issue 1, 2013, Pages 75-83

  Huang, Ching Wen ^a,b   Wang, Shang Jang ^c,d   Wu, Shyh Jong ^d   Yang, Ching Chung ^e   Huang, Ming Wei ^e   Lin, Chieh Hsin ^f   Cheng, Irene H ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b PINGTUNG CHRISTIAN HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d Kaohsiung Kai Suan Psychiatric Hospital   (Taiwan)

^e TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^f CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Alzheimer's disease; Amyloid ; APOE genotype; Biometal; Plasma and serum biomarker

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; BIOLOGICAL MARKER; INTERLEUKIN 6; IRON; TAU PROTEIN; TUMOR NECROSIS FACTOR ALPHA; ZINC;

AGE; AGED; ALZHEIMER DISEASE; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CLINICAL ARTICLE; CLINICAL DEMENTIA RATING; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLAME PHOTOMETRY; HUMAN; IRON BLOOD LEVEL; MALE; MINI MENTAL STATE EXAMINATION; POPULATION RESEARCH; PROGNOSIS; PROTEIN BLOOD LEVEL; QUANTITATIVE ASSAY; TAIWAN; ZINC BLOOD LEVEL;

EID: 84876471681     PISSN: 15333175     EISSN: 19382731     Source Type: Journal    
DOI: 10.1177/1533317512467674     Document Type: Article

References (41)

1. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 2007;3(3):186-191. (Pubitemid 46825511)
2. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734-746. (Pubitemid 47058377)
3. Sarazin M, de Souza LC, Lehericy S, Dubois B. Clinical and research diagnostic criteria for Alzheimer's disease. Neuroimaging Clin N Am. 2012;22(1):23-32.
4. Hampel H, Burger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement. 2008; 4(1):38-48.
5. Craig-Schapiro R, Fagan AM, Holtzman DM. Biomarkers of Alzheimer's disease. Neurobiol Dis. 2009;35(2):128-140.
6. Roher AE, Esh CL, Kokjohn TA, et al. Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement. 2009;5(1):18-29.
7. Locascio JJ, Fukumoto H, Yap L, et al. Plasma amyloid betaprotein and C-reactive protein in relation to the rate of progression of Alzheimer disease. Arch Neurol. 2008;65(6):776-785. (Pubitemid 351831455)
8. Lui JK, Laws SM, Li QX, et al. Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging. J Alzheimers Dis. 2010;20(4):1233-1242.
9. Oh ES, Troncoso JC, Fangmark Tucker SM. Maximizing the potential of plasma amyloid-beta as a diagnostic biomarker for Alzheimer's disease. Neuromolecular Med. 2008;10(3):195-207.
10. Rojo LE, Fernandez JA, Maccioni AA, Jimenez JM, Maccioni RB. Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch Med Res. 2008;39(1):1-16. (Pubitemid 350192021)
11. Swardfager W, Lanctot K, Rothenburg L, Wong A, Cappell J, Herrmann N. A meta-Analysis of cytokines in Alzheimer's disease. Biol Psychiatry. 2010;68(10):930-941.
12. Bush AI. Copper, zinc, and the metallobiology of Alzheimer disease. Alzheimer Dis Assoc Disord. 2003;17(3):147-150. (Pubitemid 37205705)
13. Bush AI, Masters CL, Tanzi RE. Copper, beta-Amyloid, and Alzheimer's disease: tapping a sensitive connection. Proc Natl Acad Sci U S A. 2003;100(20):11193-11194. (Pubitemid 37205909)
14. Baum L, Chan I, Cheung S, et al. Serum zinc is decreased in Alzheimer's disease and serum arsenic correlates positively with cognitive ability. Biometals. 2010:23(1):173-179.
15. Rulon LL, Robertson JD, Lovell MA, Deibel MA, Ehmann WD, Markesber WR. Serum zinc levels and Alzheimer's disease. Biol Trace Elem Res. 2000;75(1-3):79-85. (Pubitemid 30470256)
16. Hong CJ, Liu TY, Liu HC, et al. Epsilon 4 allele of apolipoprotein E increases risk of Alzheimer's disease in a Chinese population. Neurology. 1996;46(6):1749-1751. (Pubitemid 26185808)
17. Liu HC, Hong CJ, Wang SJ, et al. ApoE genotype in relation to AD and cholesterol: a study of 2,326 Chinese adults. Neurology. 1999;53(5):962-966. (Pubitemid 29442110)
18. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Kokmen E, Tangelos EG. Aging, memory, and mild cognitive impairment. Int Psychogeriatr. 1997;9(suppl 1):65-69. (Pubitemid 28045341)
19. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
20. Dooneief G, Marder K, Tang MX, Stern Y. The clinical dementia rating scale: community-based validation of "profound" and "terminal" stages. Neurology. 1996;46(6):1746-1749. (Pubitemid 26185807)
21. Brewer GJ, Kanzer SH, Zimmerman EA, et al. Subclinical zinc deficiency in Alzheimer's disease and Parkinson's disease. Am J Alzheimers Dis Other Demen. 2010;25(7):572-575.
22. Dong J, Robertson JD, Markesbery WR, Lovell MA. Serum zinc in the progression of Alzheimer's disease. J Alzheimers Dis. 2008; 15(3):443-450.
23. Burnet FM. A possible role of zinc in the pathology of dementia. Lancet. 1981;1(8213):186-188. (Pubitemid 11163115)
24. Fabris N, Mocchegiani E. Zinc, human diseases and aging. Aging (Milano). 1995;7(2):77-93.
25. Vasto S,MocchegianiE,MalavoltaM, et al. Zinc and inflammatory/immune response in aging. Ann N Y Acad Sci. 2007;1100:111-122. (Pubitemid 47092643)
26. Faux NG, Ritchie CW, Gunn A, et al. PBT2 rapidly improves cognition in Alzheimer's disease: additional phase II analyses. J Alzheimers Dis. 2010;20(2):509-516.
27. Prasad AS, Fitzgerald JT, Hess JW, Kaplan J, Pelen F, Dardenne M. Zinc deficiency in elderly patients. Nutrition. 1993;9(3):218-224. (Pubitemid 23183318)
28. Rukgauer M, Klein J, Kruse-Jarres JD. Reference values for the trace elements copper, manganese, selenium, and zinc in the serum/plasma of children, adolescents, and adults. J Trace Elem Med Biol. 1997;11(2):92-98. (Pubitemid 27337012)
29. Keller HH. Malnutrition in institutionalized elderly: how and why? J Am Geriatr Soc. 1993;41(11):1212-1218. (Pubitemid 23324871)
30. Haines A, Iliffe S, Morgan P, Dormandy T, Wood B. Serum aluminium and zinc and other variables in patients with and without cognitive impairment in the community. Clin Chim Acta. 1991;198(3):261-266.
31. Molina JA, Jimenez-Jimenez FJ, Aguilar MV, et al. Cerebrospinal fluid levels of transition metals in patients with Alzheimer's disease. J Neural Transm. 1998;105(4-5):479-488. (Pubitemid 28365030)
32. Kim SM, Song J, Kim S, et al. Identification of peripheral inflammatory markers between normal control and Alzheimer's disease. BMC Neurol. 2011;11:51.
33. Paganelli R, Di Iorio A, Patricelli L, et al. Proinflammatory cytokines in sera of elderly patients with dementia: levels in vascular injury are higher than those of mild-moderate Alzheimer's disease patients. Exp Gerontol. 2002;37(2-3): 257-263. (Pubitemid 34073542)
34. Alvarez XA, Franco A, Fernandez-Novoa L, Cacabelos R. Blood levels of histamine, IL-1 beta, and TNF-Alpha in patients with mild to moderate Alzheimer disease. Mol Chem Neuropathol. 1996;29(2-3):237-252. (Pubitemid 27016932)
35. Hager K, Machein U, Krieger S, Platt D, Seefried G, Bauer J. Interleukin-6 and selected plasma proteins in healthy persons of different ages. Neurobiol Aging. 1994;15(6):771-772. (Pubitemid 24360175)
36. Vandenabeele P, Fiers W. Is amyloidogenesis during Alzheimer's disease due to an IL-1-/IL-6-mediated 'acute phase response' in the brain? Immunol Today. 1991;12(7):217-219.
37. Chao CC, Ala TA, Hu S, et al. Serum cytokine levels in patients with Alzheimer's disease. Clin Diagn Lab Immunol. 1994;1(4): 433-436. (Pubitemid 2111069)
38. Ershler WB, Keller ET. Age-Associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med. 2000;51:245-270. (Pubitemid 30216036)
39. Schupf N, Tang MX, Fukuyama H, et al. Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci U S A. 2008;105(37):14052-14057.
40. Sundelof J, Giedraitis V, Irizarry MC, et al. Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. Arch Neurol. 2008; 65(2):256-263. (Pubitemid 351240790)
41. Cosentino SA, Stern Y, Sokolov E, et al. Plasma ss-Amyloid and cognitive decline. Arch Neurol. 2010;67(12):1485-1490.